143 related articles for article (PubMed ID: 34308004)
41. Targeting the vital non-structural proteins (NSP12, NSP7, NSP8 and NSP3) from SARS-CoV-2 and inhibition of RNA polymerase by natural bioactive compound naringenin as a promising drug candidate against COVID-19.
Aleebrahim-Dehkordi E; Ghoshouni H; Koochaki P; Esmaili-Dehkordi M; Aleebrahim E; Chichagi F; Jafari A; Hanaei S; Heidari-Soureshjani E; Rezaei N
J Mol Struct; 2023 Sep; 1287():135642. PubMed ID: 37131962
[TBL] [Abstract][Full Text] [Related]
42. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
43.
Wu Y; Chang KY; Lou L; Edwards LG; Doma BK; Xie ZR
Inform Med Unlocked; 2020; 21():100461. PubMed ID: 33102688
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and greener pastures biological study of bis-thiadiazoles as potential Covid-19 drug candidates.
Said MA; Riyadh SM; Al-Kaff NS; Nayl AA; Khalil KD; Bräse S; Gomha SM
Arab J Chem; 2022 Sep; 15(9):104101. PubMed ID: 35845755
[TBL] [Abstract][Full Text] [Related]
45. Insighting isatin derivatives as potential antiviral agents against NSP3 of COVID-19.
Ilyas M; Muhammad S; Iqbal J; Amin S; Al-Sehemi AG; Algarni H; Alarfaji SS; Alshahrani MY; Ayub K
Chem Zvesti; 2022; 76(10):6271-6285. PubMed ID: 35757111
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of bioactive compounds from
Roy A; Menon T
Vegetos; 2022; 35(2):404-414. PubMed ID: 34803247
[TBL] [Abstract][Full Text] [Related]
47. Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain.
Rabie AM
J Mol Struct; 2021 Dec; 1246():131106. PubMed ID: 34305173
[TBL] [Abstract][Full Text] [Related]
48. Repurposing Antipsychotic Agents Against Targets of Angiogenesis Pathways for Cancer Therapy: An
Kanmodi R; Bankole H; Oddiri R; Arowosegbe M; Alabi R; Rahmon S; Ahmodu O; AbdulRasheed B; Muritala R
Curr Drug Discov Technol; 2023; 20(6):38-46. PubMed ID: 37282639
[TBL] [Abstract][Full Text] [Related]
49. 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach.
Murali M; Nair B; Vishnu VR; Aneesh TP; Nath LR
Mol Divers; 2023 Oct; 27(5):2353-2363. PubMed ID: 36357813
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach.
Shahabadi N; Zendehcheshm S; Mahdavi M; Khademi F
Inform Med Unlocked; 2021; 26():100745. PubMed ID: 34568544
[TBL] [Abstract][Full Text] [Related]
51. The Computational Preventive Potential of the Rare Flavonoid, Patuletin, Isolated from
Metwaly AM; Elkaeed EB; Alsfouk BA; Saleh AM; Mostafa AE; Eissa IH
Plants (Basel); 2022 Jul; 11(14):. PubMed ID: 35890520
[TBL] [Abstract][Full Text] [Related]
52. Scalable Inhibitors of the Nsp3-Nsp4 Coupling in SARS-CoV-2.
Azizogli AR; Pai V; Coppola F; Jafari R; Dodd-O JB; Harish R; Balasubramanian B; Kashyap J; Acevedo-Jake AM; Král P; Kumar VA
ACS Omega; 2023 Feb; 8(6):5349-5360. PubMed ID: 36798146
[TBL] [Abstract][Full Text] [Related]
53. Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System.
Naman ZT; Kadhim S; Al-Isawi ZJK; Butch CJ; Muhseen ZT
Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745660
[TBL] [Abstract][Full Text] [Related]
54. Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex.
Haritha M; Suresh CH
J Biomol Struct Dyn; 2023; 41(15):7354-7364. PubMed ID: 36099187
[TBL] [Abstract][Full Text] [Related]
55. Repurposing of known drugs for COVID-19 using molecular docking and simulation analysis.
Bhanu P; Setlur AS; K C; Niranjan V; Hemandhar Kumar N; Buchke S; Kumar J; Rani A; Tiwari SM; Mishra V
Bioinformation; 2023; 19(2):149-159. PubMed ID: 37814677
[TBL] [Abstract][Full Text] [Related]
56. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An
Muhammad S; Hassan SH; Al-Sehemi AG; Shakir HA; Khan M; Irfan M; Iqbal J
Chem Phys Lett; 2021 Mar; 767():138379. PubMed ID: 33518774
[TBL] [Abstract][Full Text] [Related]
57. Designing of Thiazolidinones for COVID-19 and its Allied Diseases: An
Raza MA; Farwa U; Ain NQU; Ishaque F; Yaseen M; Naveed M; Shabbir MA
ChemistrySelect; 2022 Sep; 7(36):e202201793. PubMed ID: 36249082
[No Abstract] [Full Text] [Related]
58. Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-
Suleimen YM; Jose RA; Mamytbekova GK; Suleimen RN; Ishmuratova MY; Dehaen W; Alsfouk BA; Elkaeed EB; Eissa IH; Metwaly AM
Plants (Basel); 2022 Aug; 11(15):. PubMed ID: 35956550
[TBL] [Abstract][Full Text] [Related]
59. Repurposing of Food and Drug Admnistration (FDA) approved library to identify a potential inhibitor of
Vemula D; Mohanty S; Bhandari V
Heliyon; 2024 Mar; 10(6):e27602. PubMed ID: 38509977
[TBL] [Abstract][Full Text] [Related]
60. Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes.
Flori L; Brogi S; Sirous H; Calderone V
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
